<p><strong>Special patient groups</strong>: There is no need to adjust the dose in elderly patients.<br />
<br />
<strong>Hepatic or renal</strong>: There are no data available for use of this inhaler in patients with hepatic or renal impairment.<br />
<br />
<strong>Paediatric population</strong>: It is recommended that the height of children receiving prolonged treatment with inhaled corticosteroids is regularly monitored. If growth is slowed, therapy should be reviewed with the aim of reducing the dose of inhaled corticosteroid, if possible, to the lowest dose at which effective control of asthma is maintained. In addition, consideration should be given to referring the patient to a paediatric respiratory specialist.<br />
<br />
Only limited data are available in respect of the use of this&nbsp;inhaler in children under 12 years of age. This inhaler is not recommended for use in children under 12 years of age until further data become available.</p>